WO2026003756 - METHODS OF DETERMINING PHARMACODYNAMIC ACTIVITY AND TREATMENT EFFICACY
National phase entry is expected:
Publication Number
WO/2026/003756
Publication Date
02.01.2026
International Application No.
PCT/IB2025/056463
International Filing Date
25.06.2025
Title **
[English]
METHODS OF DETERMINING PHARMACODYNAMIC ACTIVITY AND TREATMENT EFFICACY
[French]
MÉTHODES POUR DÉTERMINER L'ACTIVITÉ PHARMACODYNAMIQUE ET L'EFFICACITÉ DU TRAITEMENT
Applicants **
REPARE THERAPEUTICS INC.
Inventors
ZIMMERMANN, Michal
KIM, Hyeyeon
Priority Data
63/663,753
25.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7123 | |
| EPO | Filing, Examination, Granting | 113002 | |
| Japan | Filing, Examination, Granting | 4830 | |
| South Korea | Filing, Examination, Granting | 8342 | |
| USA | Filing, Examination, Granting | 26590 |
Total:
159,887
Contact Us
Abstract[English]
Disclosed are methods for determining the pharmacodynamic activity of one or more compounds by measurement of focal accumulation of CIP2A. Further disclosed are methods of determining the effectiveness of a treatment with one or more compounds b measurement of focal accumulation of CIP2A. Compounds of the invention may be Polθ kinase inhibitors or PARP inhibitors.[French]
L'invention concerne des méthodes permettant de déterminer l'activité pharmacodynamique d'un ou plusieurs composés par la mesure de l'accumulation focale de CIP2A. La présente invention concerne également des méthodes permettant de déterminer l'efficacité d'un traitement à l'aide d'un ou plusieurs composés par la mesure de l'accumulation focale de CIP2A. Les composés de l'invention peuvent être des inhibiteurs de la Polθ kinase ou des inhibiteurs de PARP.